META Dynamic Reaches Distribution Deal With Omniscient Neurotechnology

META Dynamic Inc. and Omniscient Neurotechnology have forged a distribution partnership to bring Omniscient’s Quicktome neurological visualization and planning capabilities to META’s Outsourced Surgical Solutions (OSS) program through integration with surgical navigation systems such as the CBYON Eclipse surgical navigation system from META’s partner company, MSSI.
 
Designed by neurosurgeons and data scientists, the Quicktome Software Suite is a cloud-based connectomic analysis platform that allows neurosurgeons to visualize and understand a patient’s brain networks before performing life-changing neurosurgery. These brain networks are responsible for everything from language to movement to thought, and when impacted, can cause costly complications for the patient and hospital alike.  Quicktome is reportedly the only commercially available platform that can automatically map a patient’s unique connectome, informing surgical decision making. Using artificial intelligence, Quicktome analyzes millions of data points derived from a patient’s MRI results.
 
“The ability for META’s OSS program to include Quicktome connectomic analysis brings the latest advancements and technologies to our customers,” said Brian Moore, META’s Business Development director. “We are thrilled to be a channel partner with Omniscient in expanding their customer base.”
 
Recognized for its OSS program, META optimizes image-guided surgery with expert clinical case support and CBYON Eclipse navigation system rental options. These offerings enhance operating room efficiency and productivity and are now bolstered with Quicktome software. Founded in 2002, META Dynamic Inc. develops surgical navigation technology and image-guided surgical support. The META team has extensive experience in cranial, spine, and ENT image-guided surgery procedures on all leading surgical navigation platforms and offers clinical support.  
 
Omniscient (o8t) uses AI to decode the human brain, a field known as connectomics. The company is an artificial intelligence research hub that creates advanced technologies to conquer the problems and enhance the human brain’s potential.  Already used by neurosurgeons to visualize the brain’s pathways prior to a procedure, Omniscient’s connectomics AI platform—Quicktome—can potentially help conquer conditions such as Alzheimer’s disease and depression through precision brain medicine.